CTI BioPharma Stock Company Profile
3101 Western Avenue, Suite 800
Seattle WA 98121
206 282 7100
www.ctibiopharma.com
Industry: Biotechnology
Sector: Healthcare
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
